| 1 |
Wu Y, Xu S, Cheng S, Yang J, Wang Y. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J Ovarian Res 2023;16:6. [PMID: 36611214 DOI: 10.1186/s13048-023-01094-5] [Reference Citation Analysis]
|
| 2 |
Alexandrov V, Kirpich A, Kantidze O, Gankin Y. A multi-reference poly-conformational method for in silico design, optimization, and repositioning of pharmaceutical compounds illustrated for selected SARS-CoV-2 ligands. PeerJ 2022;10:e14252. [PMID: 36447514 DOI: 10.7717/peerj.14252] [Reference Citation Analysis]
|
| 3 |
Colic E, Patel PU, Kent OA. Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma. OTT 2022;Volume 15:1331-1346. [DOI: 10.2147/ott.s361512] [Reference Citation Analysis]
|
| 4 |
Channathodiyil P, May K, Segonds-Pichon A, Smith PD, Cook SJ, Houseley J. Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance. NAR Cancer 2022;4:zcac032. [PMID: 36267209 DOI: 10.1093/narcan/zcac032] [Reference Citation Analysis]
|
| 5 |
Abbotts R, Dellomo AJ, Rassool FV. Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use. Cancers 2022;14:2640. [DOI: 10.3390/cancers14112640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 6 |
Stukan AI, Goryainova AY, Sharov SV, Goncharova OA, Khachmamuk ZK, Durov VV. Causes of resistance to PARP inhibitors and ways to overcome it. Case report of aggressive <i>BRCA</i>-related breast cancer. Opuholi ženskoj reproduktivnoj sistemy 2022;18:54-65. [DOI: 10.17650/1994-4098-2022-18-1-54-65] [Reference Citation Analysis]
|
| 7 |
Pham MM, Hinchcliff E, Avila M, Westin SN. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance. Cancer J 2021;27:491-500. [PMID: 34904812 DOI: 10.1097/PPO.0000000000000562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI. Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. NPJ Precis Oncol 2021;5:92. [PMID: 34667258 DOI: 10.1038/s41698-021-00232-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 9 |
Voutsadakis IA. Mutations of p53 associated with pancreatic cancer and therapeutic implications. Ann Hepatobiliary Pancreat Surg 2021;25:315-27. [PMID: 34402431 DOI: 10.14701/ahbps.2021.25.3.315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Oh SY, Rahman S, Sparano JA. Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. Expert Opin Pharmacother 2021;22:981-1003. [PMID: 33646064 DOI: 10.1080/14656566.2021.1876662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 11 |
Channathodiyil P, Segonds-pichon A, Smith PD, Cook SJ, Houseley J. DNA replication during acute MEK inhibition drives acquisition of resistance through amplification of the BRAF oncogene.. [DOI: 10.1101/2021.03.23.436572] [Reference Citation Analysis]
|
| 12 |
Kasi A, Al-Jumayli M, Park R, Baranda J, Sun W. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. J Pancreat Cancer 2020;6:107-15. [PMID: 33376937 DOI: 10.1089/pancan.2020.0010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI. Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations.. [DOI: 10.1101/2020.07.25.20146431] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 14 |
Lee EK, Matulonis UA. PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies. Cancers (Basel) 2020;12:E2054. [PMID: 32722408 DOI: 10.3390/cancers12082054] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 15 |
Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA. Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers (Basel) 2020;12:E972. [PMID: 32295316 DOI: 10.3390/cancers12040972] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 16 |
de Lima DC, Rodrigues SV, Boaventura GT, Cho HY, Chen TC, Schönthal AH, Da Fonseca CO. Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats. Drug Test Anal 2020;12:268-79. [PMID: 31800149 DOI: 10.1002/dta.2722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 17 |
Labrie M, Kendsersky ND, Ma H, Campbell L, Eng J, Chin K, Mills GB. Proteomics advances for precision therapy in ovarian cancer. Expert Rev Proteomics 2019;16:841-50. [PMID: 31512530 DOI: 10.1080/14789450.2019.1666004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 18 |
Lakkakula BVKS, Farran B, Lakkakula S, Peela S, Yarla NS, Bramhachari PV, Kamal MA, Saddala MS, Nagaraju GP. Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles. Seminars in Cancer Biology 2019;56:149-67. [DOI: 10.1016/j.semcancer.2018.09.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 19 |
Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 2019;10:3533-46. [PMID: 31191824 DOI: 10.18632/oncotarget.26947] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
